Author:
Fujita Ken-ichi,Masuo Yusuke,Okumura Hidenori,Watanabe Yusuke,Suzuki Hiromichi,Sunakawa Yu,Shimada Ken,Kawara Kaori,Akiyama Yuko,Kitamura Masanori,Kunishima Munetaka,Sasaki Yasutsuna,Kato Yukio
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference31 articles.
1. Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, et al. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res. 2014;31(1):204–15.
2. Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 1997;57(10):1934–8.
3. Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, et al. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998;58(22):5137–43.
4. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001;288(4):827–32.
5. Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, et al. Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab Dispos. 2011;39(2):161–4.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献